CD160 (cluster of differentiation 160), also known as natural killer cell receptor BY55, plays a role in human cancers such as chronic lymphocytic leukemia (CLL) (Bozorgmehr et al., 2021), colon cancer and melanoma (Chabot et al., 2011; Saleh et al., 2020), and pancreatic cancer (Liu et al., 2020). This evidence concerns the gene CD160 and cancer.